Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Lorcaserin decreases the reinforcing effects of heroin, but not food, in rhesus monkeys
Stephen J. Kohut, Jack Bergman
European Journal of Pharmacology (2018) Vol. 840, pp. 28-32
Open Access | Times Cited: 31

Showing 1-25 of 31 citing articles:

Single nuclei transcriptomics in human and non-human primate striatum in opioid use disorder
BaDoi N. Phan, Madelyn H. Ray, Xiangning Xue, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 17
NIDA’s medication development priorities in response to the Opioid Crisis: ten most wanted
Kurt Rasmussen, David A. White, Jane B. Acri
Neuropsychopharmacology (2018) Vol. 44, Iss. 4, pp. 657-659
Open Access | Times Cited: 110
Lorcaserin: A review of its preclinical and clinical pharmacology and therapeutic potential
Guy A. Higgins, Paul Fletcher, William Shanahan
Pharmacology & Therapeutics (2019) Vol. 205, pp. 107417-107417
Closed Access | Times Cited: 67
Lorcaserin maintenance fails to attenuate heroin vs. food choice in rhesus monkeys
E. Andrew Townsend, S. Stevens Negus, Justin L. Poklis, et al.
Drug and Alcohol Dependence (2020) Vol. 208, pp. 107848-107848
Open Access | Times Cited: 30
Effects of lorcaserin on oxycodone self-administration and subjective responses in participants with opioid use disorder
Laura Brandt, Jermaine D. Jones, Suky Martinez, et al.
Drug and Alcohol Dependence (2020) Vol. 208, pp. 107859-107859
Open Access | Times Cited: 29
The psychedelic drug DOI reduces heroin motivation by targeting 5-HT2A receptors in a heroin and alcohol co-use model
J. Alfred Bonilla, Giuseppe Giannotti, Nathaniel P. Kregar, et al.
Neuropharmacology (2024) Vol. 261, pp. 110163-110163
Closed Access | Times Cited: 3
Learning from lorcaserin: lessons from the negative clinical trial of lorcaserin to treat cocaine use disorder
S. Stevens Negus, Matthew L. Banks
Neuropsychopharmacology (2020) Vol. 45, Iss. 12, pp. 1967-1973
Open Access | Times Cited: 23
The 5‐HT2C receptor as a therapeutic target for alcohol and methamphetamine use disorders: A pilot study in treatment‐seeking individuals
Erin J. Campbell, Yvonne Bonomo, Adam Pastor, et al.
Pharmacology Research & Perspectives (2021) Vol. 9, Iss. 3
Open Access | Times Cited: 18
Prefrontal-Limbic Circuitry Is Associated With Reward Sensitivity in Nonhuman Primates
Kwang‐Hyun Hur, Steven L. Meisler, Walid Yassin, et al.
Biological Psychiatry (2024) Vol. 96, Iss. 6, pp. 473-485
Closed Access | Times Cited: 2
Endogenous opiates and behavior: 2019
Richard J. Bodnar
Peptides (2021) Vol. 141, pp. 170547-170547
Closed Access | Times Cited: 15
5HT‐2C agonist lorcaserin decreases cannabis self‐administration in daily cannabis smokers
Caroline A. Arout, Ziva D. Cooper, Stephanie Collins Reed, et al.
Addiction Biology (2021) Vol. 26, Iss. 4
Open Access | Times Cited: 13
Adjunctive effect of the serotonin 5-HT2C receptor agonist lorcaserin on opioid-induced antinociception in mice
Salvador Sierra, Kumiko Lippold, David L. Stevens, et al.
Neuropharmacology (2020) Vol. 167, pp. 107949-107949
Open Access | Times Cited: 14
Improving Translational Research Outcomes for Opioid Use Disorder Treatments
Jermaine D. Jones, Neil B. Varshneya, Thomas J. Hudzik, et al.
Current Addiction Reports (2021) Vol. 8, Iss. 1, pp. 109-121
Open Access | Times Cited: 11
Lorcaserin: Worthy of Further Insights? Results from Recent Research
Marianna Mazza, Georgios D. Kotzalidis, Giuseppe Marano, et al.
CNS & Neurological Disorders - Drug Targets (2023) Vol. 23, Iss. 3, pp. 278-283
Closed Access | Times Cited: 4
Molecular and structural insights into the 5‐HT2C receptor as a therapeutic target for substance use disorders
Maleesha Ubhayarathna, Christopher J. Langmead, Natalie Diepenhorst, et al.
British Journal of Pharmacology (2023) Vol. 181, Iss. 22, pp. 4414-4429
Open Access | Times Cited: 4
The serotonin 2C receptor agonist lorcaserin, alone and in combination with the opioid receptor antagonist naltrexone, attenuates binge‐like ethanol drinking
Rayane I. Tabbara, Zhaoxia Li, Paul Fletcher, et al.
Addiction Biology (2021) Vol. 26, Iss. 5
Closed Access | Times Cited: 10
Biological Sex Modulates the Efficacy of 2,5-dimethoxy-4-iodoamphetamine (DOI) to Mitigate Fentanyl Demand
Alice J McQueney, Erik J. Garcia
Drug and Alcohol Dependence (2024) Vol. 263, pp. 112426-112426
Closed Access | Times Cited: 1
Exploring Novel Pharmacotherapy Candidates for Cannabis Use Disorder: Uncovering Promising Agents on the Horizon by Mechanism of Action
Myra Alayoubi, Brittany A. Henry, Catherine M. Cahill, et al.
Drugs (2024) Vol. 84, Iss. 11, pp. 1395-1417
Open Access | Times Cited: 1
Interactions between lorcaserin and opioids: Ventilation and food-versus-drug choice
David R. Maguire
Pharmacology Biochemistry and Behavior (2023) Vol. 234, pp. 173673-173673
Open Access | Times Cited: 3
Lorcaserin treatment for extended-release naltrexone induction and retention for opioid use disorder individuals: A pilot, placebo-controlled randomized trial
Frances R. Levin, John J. Mariani, Martina Pavlicová, et al.
Drug and Alcohol Dependence (2021) Vol. 219, pp. 108482-108482
Open Access | Times Cited: 7
Effects of buprenorphine/lorcaserin mixtures on preference for heroin, cocaine, or saline over food using a concurrent choice procedure in rhesus monkeys
Lisa R. Gerak, Charles P. France
Drug and Alcohol Dependence (2021) Vol. 227, pp. 108991-108991
Open Access | Times Cited: 7
Neural circuits controlling choice behavior in opioid addiction
Victoria N. Chang, Jamie Peters
Neuropharmacology (2022) Vol. 226, pp. 109407-109407
Open Access | Times Cited: 5
Biphasic reward effects are characteristic of both lorcaserin and drugs of abuse: implications for treatment of substance use disorders
Ken W. Grasing, Kim Burnell, Alok De
Behavioural Pharmacology (2022) Vol. 33, Iss. 4, pp. 238-248
Open Access | Times Cited: 4
Effects of pimavanserin and lorcaserin on alcohol self-administration and reinstatement in male and female rats
Paul Fletcher, Zhaoxia Li, Ji X, et al.
Neuropharmacology (2022) Vol. 215, pp. 109150-109150
Closed Access | Times Cited: 4
Effects of 5-HT2C receptor stimulation in male mice on behaviour and Fos expression: Feeding, reward and impulsivity
Paul Fletcher, Arya Rahbarnia, Zhaoxia Li, et al.
Behavioural Brain Research (2023) Vol. 447, pp. 114438-114438
Closed Access | Times Cited: 2
Page 1 - Next Page

Scroll to top